CURANEX PHARMACEUTICALS INC

CURXNASDAQ

🏆 #3763 by market capUS Equity

$0.20▲ $0.01 (+3.68%)

Live

1h—

24h▲ 3.7%

7d▼ 0.3%

14d▲ 4.0%

30d▼ 7.3%

1y—

🏦Market Cap

$6M

Small Cap

📈Revenue Growth (YoY)

—

📊Gross Margin

—

💵FCF Margin

—

⚖️P/S Ratio

—

Otter Score

Weak

Trading Snapshot

Day Range: $0.20 – $0.20
52-Week Range: $0.26 – $9.18
Volume: $2.23B
Avg Volume: $2.21B
Shares Outstanding: 28.4M
Next Earnings: Oct 22, 2026

Fundamentals Snapshot

Annual Revenue: $492,971
Last Q Revenue: $121,768
P/E Ratio: —
P/S Ratio: —
EPS (TTM): $-0.26
Dividend Yield: —

Why Investors Own CURX

✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
✓Healthy economics — 32% gross margin and 14% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$492,971▲ +11.7% YoY

Gross Margin (TTM)

31.6%▲ +3.1% YoY

Operating Income (TTM)

$136,060▲ +11.7% YoY

Free Cash Flow (TTM)

$68,030▲ +11.7% YoY

About CURANEX PHARMACEUTICALS INC

Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.

🦦